Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 3Recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Anxiety Disorders 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Propranolol × Gynecologic × Clear all
NCT01902966 2021-10-12

Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)

M.D. Anderson Cancer Center

Phase NA Terminated
6 enrolled 8 charts
Gynecologic

Anxiety Disorders, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡